John M Rhee1,2, Weilong J Shi1, Mathew Cyriac2, Jin Y Kim1, Feifei Zhou3, Kirk A Easley4, Anuj Patel2. 1. School of Medicine. 2. Department of Orthopaedic Surgery, Emory University. 3. Department of Orthopaedics, Third Hospital, Peking University. 4. Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA.
Abstract
STUDY DESIGN: Prospective Cohort Study. OBJECTIVE: The objective of this study is to evaluate and validate a patient-derived version of the modified Japanese Orthopaedic Association (the "P-mJOA") that a patient can complete along with other patient-derived outcome measures. SUMMARY OF BACKGROUND DATA: The modified Japanese Orthopaedic Association (mJOA) is a validated instrument widely used in the assessment of cervical myelopathy; however, it is not a patient-derived outcome. If available and reliable, a patient-derived version of the mJOA (P-mJOA) could facilitate research because the data would be immediately available upon patient completion and also remove any potential physician bias. Currently, there is no patient-derived myelopathy survey with the widespread acceptance of the mJOA. METHODS: The P-mJOA was created by very slightly modifying the verbiage of the mJOA to make it possible for a patient to complete the instrument while maintaining the questionnaire's core structure. A total of 100 consecutive consenting patients with cervical myelopathy were enrolled. After the patient completed the P-mJOA, the mJOA was scored by a physician blinded to the P-mJOA result. RESULTS: The P-mJOA and the mJOA had identical mean scores of 14.7 (mean difference±SD: 0.0±1.5; P=0.89). Several measures of reliability demonstrated agreement between the 2 surveys, including strong agreement with the intraclass correlation coefficient and Spearman ρ (both 0.83) and moderate to substantial agreement with weighted κ values (0.55 to 0.66). In addition, 67% of patients preferred to fill out the P-mJOA themselves, suggesting low patient burden. CONCLUSIONS: The P-mJOA provided identical mean scores to the mJOA in assessing myelopathy with moderate to strong agreement. Comprised of the same 4 questions as the mJOA but slightly reworded for patient comprehension, the P-mJOA also demonstrated low patient burden in completing the survey. We believe the P-mJOA is a promising tool in cervical myelopathy research with the benefits of a patient-derived outcome measure and low patient burden. LEVEL OF EVIDENCE: Level II.
STUDY DESIGN: Prospective Cohort Study. OBJECTIVE: The objective of this study is to evaluate and validate a patient-derived version of the modified Japanese Orthopaedic Association (the "P-mJOA") that a patient can complete along with other patient-derived outcome measures. SUMMARY OF BACKGROUND DATA: The modified Japanese Orthopaedic Association (mJOA) is a validated instrument widely used in the assessment of cervical myelopathy; however, it is not a patient-derived outcome. If available and reliable, a patient-derived version of the mJOA (P-mJOA) could facilitate research because the data would be immediately available upon patient completion and also remove any potential physician bias. Currently, there is no patient-derived myelopathy survey with the widespread acceptance of the mJOA. METHODS: The P-mJOA was created by very slightly modifying the verbiage of the mJOA to make it possible for a patient to complete the instrument while maintaining the questionnaire's core structure. A total of 100 consecutive consenting patients with cervical myelopathy were enrolled. After the patient completed the P-mJOA, the mJOA was scored by a physician blinded to the P-mJOA result. RESULTS: The P-mJOA and the mJOA had identical mean scores of 14.7 (mean difference±SD: 0.0±1.5; P=0.89). Several measures of reliability demonstrated agreement between the 2 surveys, including strong agreement with the intraclass correlation coefficient and Spearman ρ (both 0.83) and moderate to substantial agreement with weighted κ values (0.55 to 0.66). In addition, 67% of patients preferred to fill out the P-mJOA themselves, suggesting low patient burden. CONCLUSIONS: The P-mJOA provided identical mean scores to the mJOA in assessing myelopathy with moderate to strong agreement. Comprised of the same 4 questions as the mJOA but slightly reworded for patient comprehension, the P-mJOA also demonstrated low patient burden in completing the survey. We believe the P-mJOA is a promising tool in cervical myelopathy research with the benefits of a patient-derived outcome measure and low patient burden. LEVEL OF EVIDENCE: Level II.
Authors: Benjamin Davies; Oliver Mowforth; Iwan Sadler; Bizhan Aarabi; Brian Kwon; Shekar Kurpad; James S Harrop; Jefferson R Wilson; Robert Grossman; Michael G Fehlings; Mark Kotter Journal: BMJ Open Date: 2019-10-10 Impact factor: 2.692
Authors: Luca Papavero; Markus Pietrek; Carlos Joan Marques; Gregor Schmeiser Journal: J Neurol Surg A Cent Eur Neurosurg Date: 2021-10-11 Impact factor: 1.268
Authors: Max B Butler; Oliver D Mowforth; Abdul Badran; Michelle Starkey; Timothy Boerger; Iwan Sadler; Julia Tabrah; Caroline Treanor; Lucy Cameron Grad Dip Phys; Sukhvinder Kalsi-Ryan; Rodney J Laing; Benjamin M Davies; Mark R N Kotter Journal: Global Spine J Date: 2020-10-01
Authors: Benjamin M Davies; Colin Munro; Danyal Z Khan; Siobhan M Fitzpatrick; Bryn Hilton; Oliver D Mowforth; Angus G K McNair; Iwan Sadler; Mark R N Kotter Journal: Global Spine J Date: 2020-11-18
Authors: Timothy Boerger; Ali Alsouhibani; Oliver Mowforth; Joseph Hamilton; Abdul Lalkhen; Benjamin M Davies; Mark R N Kotter Journal: Global Spine J Date: 2021-02-25